Metabolic Abnormalities, Cardiovascular Disease, and Metabolic Syndrome in Adult Rheumatoid Arthritis Patients: Current Perspectives and Clinical Implications
Pedro Santos-Moreno,Gabriel-Santiago Rodríguez-Vargas,Susan Martínez,Linda Ibatá,Adriana Rojas-Villarraga
DOI: https://doi.org/10.2147/OARRR.S285407
2022-11-04
Open Access Rheumatology: Research and Reviews
Abstract:Pedro Santos-Moreno, 1 Gabriel-Santiago Rodríguez-Vargas, 1 Susan Martínez, 2 Linda Ibatá, 2 Adriana Rojas-Villarraga 3 1 Rheumatology, Biomab IPS, Bogotá, Colombia; 2 Epidemiology, Epithink Health Consulting, Bogotá, Colombia; 3 Research Institute, Fundación Universitaria de Ciencias de la Salud–FUCS, Bogotá, Colombia Correspondence: Pedro Santos-Moreno, Rheumatology, Biomab IPS, Calle 48 &num 13-86, Bogotá, Colombia, Tel +57 320 8094232, Email Aim: Rheumatoid arthritis is a prevalent worldwide disease, associated with an increased risk of multiple metabolic abnormalities that generate a higher disease burden. Objective: To gather the available evidence on the epidemiology, pathophysiology, current perspectives, clinical implications and prognosis of metabolic abnormalities in patients with rheumatoid arthritis. Methods: This is a narrative literature review. Search was conducted in PubMed, OVID, and Taylor & Francis databases, using the following MeSH terms: "Arthritis Rheumatoid", "Metabolic Diseases", and "Metabolic Syndrome". Results: This study describes the main metabolic manifestations of rheumatoid arthritis. Research has recognized that rheumatoid arthritis and metabolic abnormalities share pathophysiological mechanisms with an additive effect that increases cardiovascular risk. In that context, appropriate antirheumatic treatment can also impact on cardiovascular risk. Conclusion: There are metabolic abnormalities in rheumatoid arthritis patients that increase cardiovascular risk. Therefore, it is crucial to evaluate cardiovascular risk to provide appropriate comprehensive management to reduce morbidity and mortality in patients with this disease. Keywords: rheumatoid arthritis, metabolic diseases, cardiovascular diseases, metabolic syndrome Rheumatoid arthritis (RA) is a systemic autoimmune disease—affecting 5 out of every 1000 peopl—with a female predominance and an increased incidence in people over 60 years old. 1 This disease is characterized by arthralgia—which is disabling in some cases—morning stiffness, and joint swelling. 2 Also, there is extra-articular involvement in other systems such as cardiovascular, respiratory, renal, and ophthalmic. 3 Besides the disease burden, these patients have an increased risk of developing metabolic abnormalities, such as diabetes mellitus (DM), arterial hypertension (AH), osteoporosis (OP), and arteriosclerosis. These alterations lead to a significant increase in cardiovascular risk (CVR), 4 mortality, and disability. 5 Although there is an increase in last decades regarding research in this topic, there is still a gap to close in order to impact CVR and to analyze the metabolic pathways abnormalities present in RA patients. 6 This review aims to gather the available evidence on the epidemiology, pathophysiology, current perspectives, clinical implications and prognosis of metabolic abnormalities in patients with rheumatoid arthritis. This is narrative literature review. Search for documents was conducted in the following databases: PubMed, OVID, and Taylor & Francis, using the following MeSH terms: "Arthritis Rheumatoid", "Metabolic Diseases", and "Metabolic Syndrome." Additional studies were sought from the reference list of certain primary studies and different reviews. We select the studies that were more relevant for the aim of the review. In 2010, the Global Burden of Disease study found that RA had a global prevalence of 0.25%, discriminated by sex with 0.35% for women and 0.13% for men. Besides, it was ranked as the 42nd cause of global disability, 7 demonstrating the high impact of RA on the disease burden worldwide. Additionally, economic studies reflect the increased financial burden of RA: this disease generates costs of approximately 83,845 per patient each year, including direct and indirect costs, such as medicines, hospitalization, and workplace absenteeism. 8 Regarding metabolic alterations, patients with RA have a high prevalence of this type of comorbidities. For example, a cross-sectional and multicenter study conducted in 2014 by Dougados et al, which included 3920 patients from 17 countries, evaluated the prevalence of comorbidities in people with RA, and it found that 40.4% of the patients had AH, 31.7% had hypercholesterolemia, and 15% had DM. 9 In another study conducted in Spain, patients with RA had a high prevalence of metabolic comorbidities. The most common were hypercholesterolemia in 45% of the population, AH in 41%, and DM in 12%. 10 Thus, these metabolic comorbidities in RA patients present an increase i -Abstract Truncated-